CarnoSyn (Beta-Alanine)

CarnoSyn is a patented, pure form of beta-alanine (β-alanine), a non-proteinogenic amino acid (C₃H₇NO₂, MW 89.09 g/mol). It contains no significant macronutrients (negligible calories, fat, carbohydrates, or complete protein per typical serving). Key bioactive compound: Beta-alanine at approximately 3,200–6,400 mg per daily serving (standard clinical dosing range). Beta-alanine is the rate-limiting precursor to carnosine (β-alanyl-L-histidine) synthesis in skeletal muscle. Oral bioavailability is high (approximately 90–95% absorption via intestinal transporter PAT1/SLC36A1). Upon ingestion, beta-alanine is taken up by skeletal muscle type II (fast-twitch) fibers via the TauT transporter, where it combines with L-histidine to form carnosine via carnosine synthase. Sustained supplementation (typically 3.2–6.4 g/day over 4–12 weeks) elevates intramuscular carnosine concentrations by approximately 40–80%. Contains no vitamins, minerals, fiber, or fat. No significant micronutrient content. The product is typically free of sugar, gluten, and common allergens. CarnoSyn is distinguished from generic beta-alanine by its patented manufacturing process ensuring >99% purity with verified absence of contaminants (heavy metals, microbial impurities). Peak plasma concentration occurs approximately 30–45 minutes post-ingestion. Paresthesia (tingling sensation) is a common, harmless side effect at single doses exceeding ~800–1,600 mg, which can be mitigated by using sustained-release formulations (SR CarnoSyn) that provide slower, more sustained absorption. Half-life in plasma is approximately 25 minutes, but the functional effect is cumulative through chronic muscle carnosine loading rather than acute dosing.